Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Assembly Biosciences Inc ASMB

Healthcare Biotechnology
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small molecule antiviral therapeutics. The Company’s pipeline includes two helicase-primase inhibitors (HPI) targeting recurrent genital herpes, an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, a clinical-stage capsid assembly modulator (CAM) designed to disrupt the replication cycle... see more

Recent & Breaking News (NDAQ:ASMB)

Assembly Bio Announces Decision to Discontinue Clinical Development of ABI-H2158

GlobeNewswire September 1, 2021

Assembly Bio Selects Fourth HBV Core Inhibitor Candidate for Advancement Into Clinical Development

GlobeNewswire August 18, 2021

Assembly Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights

GlobeNewswire August 5, 2021

Assembly Bio Announces Key Promotions to Leadership Team

GlobeNewswire August 3, 2021

Nobel Laureate Dr. Michael Houghton Appointed to Assembly Biosciences Board of Directors

GlobeNewswire July 20, 2021

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire July 2, 2021

Assembly Biosciences Presents Data from HBV Core Inhibitor Programs at the International Liver Congress(TM) EASL 2021

GlobeNewswire June 23, 2021

Assembly Biosciences to Present Data from HBV Core Inhibitor Programs at The International Liver Congress(TM) EASL 2021

GlobeNewswire June 9, 2021

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire June 4, 2021

Dr. Lisa Johnson-Pratt Joins Assembly Biosciences Board of Directors

GlobeNewswire May 24, 2021

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire May 7, 2021

Assembly Biosciences Reports First Quarter 2021 Financial Results and Recent Updates

GlobeNewswire May 6, 2021

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 5, 2021

Assembly Biosciences and Arbutus Biopharma Initiate Phase 2 Clinical Trial of Triple Combination Therapy for the Treatment of Chronic Hepatitis B Virus

GlobeNewswire February 26, 2021

Assembly Biosciences Reports Fourth Quarter and Year End 2020 Financial Results and Recent Highlights

GlobeNewswire February 25, 2021

Assembly Biosciences Updates Pipeline Strategy, Focusing on Finite and Curative Therapies for Chronic Hepatitis B Virus Infection

GlobeNewswire February 25, 2021

Assembly Bio Announces Upcoming Investor Events

GlobeNewswire February 19, 2021

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 5, 2021

Assembly Biosciences to Wind-Down Microbiome Program

GlobeNewswire December 8, 2020

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 4, 2020